Valuation: RAPT Therapeutics, Inc.

Market Cap 94Cr 82Cr 77Cr 70Cr 131.48Cr 9.01TCr 132.03Cr 925.69Cr 357.22Cr 4.58TCr 352.57Cr 344.75Cr 15TCr P/E 2023
-8.16x
P/E 2024 -0.5x
Enterprise Value 71Cr 62Cr 59Cr 53Cr 100Cr 6.83TCr 100.16Cr 702.23Cr 270.99Cr 3.47TCr 267.46Cr 261.53Cr 11TCr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
96.87%
Yield 2023 *
-
Yield 2024 -
1 day+0.07%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 18.08
Extreme 18.08
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 03/03/2026
Treasurer - 03/03/2026
Director TitleAgeSince
Director/Board Member - 03/03/2026
Director/Board Member - 03/03/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/03/26 Tender

Chief Technology Officer

1,64,742 0.5945%
03/03/26 Tender

Chief Financial Officer

2,05,703 0.7423%
03/03/26 Tender

Director

59,858 0.2160%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+192.15%-62.27% 179.41Cr
-0.31%+5.79%+47.13%+99.53% 7.09TCr
-0.87%+2.06%+39.38%+78.71% 6.25TCr
+5.36%+7.96%+32.36%+30.18% 2.63TCr
-3.21%-7.27%-17.10%+370.22% 2.62TCr
-2.64%-0.69%-0.17%-11.56% 2.41TCr
-0.20%+8.03%+25.03%-13.74% 2.07TCr
+2.12%-5.86%+161.58%+333.73% 1.57TCr
-0.22%+3.99%+45.54%+171.32% 1.45TCr
+0.73%+1.71%-5.51%+859.68% 1.42TCr
Average +0.30%+1.58%+52.04%+185.58% 2.77TCr
Weighted average by Cap. +0.18%+1.48%+36.76%+150.75%

Financials

2023 2024
Net sales - -
Net income -12Cr -10Cr -9.62Cr -8.73Cr -16Cr -1.12TCr -16Cr -115.2Cr -44Cr -569.8Cr -44Cr -43Cr -1.83TCr -13Cr -11Cr -11Cr -9.71Cr -18Cr -1.25TCr -18Cr -128.08Cr -49Cr -633.55Cr -49Cr -48Cr -2.04TCr
Net Debt -15Cr -13Cr -13Cr -11Cr -21Cr -1.46TCr -21Cr -149.87Cr -58Cr -741.32Cr -57Cr -56Cr -2.39TCr -23Cr -20Cr -19Cr -17Cr -32Cr -2.17TCr -32Cr -223.45Cr -86Cr -1.11TCr -85Cr -83Cr -3.56TCr
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!